Thirty train drivers with erectile dysfunction (ED) and arterial hypertension were examined : physical examination, blood count, urinalysis, penile laser Doppler flowmetry (LDF). ED severity was assessed by Loran-Segal questionnaire of male copulative function (MCF) and international index of erectile function (IIEF). Zidena was used in a dose 100 mg 30 min before coitus twice a weak. Examinations have detected mild and moderate ED, spastic disorders of penile microcirculation. MCF significant improvement (p < 0.05), rise of IIEF score were seen after 30 days of zidena treatment. A positive trend was observed after 15 days of treatment. LDF registered a significant (p < 0.05) improvement of microcirculation. Tissue hypoxia and ischemia lowered, blood inflow in the system of microcirculation increased. A passive mechanism of blood flow regulation, vasodilation almost corresponded to physiological standards. Administration of zidena in patients with stress-induced hypertension has improved libido, quality and duration of erection, penile microcirculation due to better tissue perfusion with blood, reduction of ischemia and blood congestion in the venules. Duration of coitus increased.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
New and Emerging Therapeutic Drugs for the Treatment of Pulmonary Arterial Hypertension: A Systematic Review.
Cureus
August 2024
Research, Ventolini's Lab, Texas Tech University Health Sciences Center, Odessa, USA.
Article Synopsis
- Pulmonary arterial hypertension (PAH) is a severe lung disease marked by elevated pulmonary arterial pressure, causing symptoms that often lead to late diagnosis and a poor prognosis, with a median life expectancy of only three years.
- The condition involves a combination of factors leading to blockage and stiffening of blood vessels in the lungs, resulting in right heart strain and potential failure.
- A systematic review of recent studies evaluated various PAH treatments, highlighting that while many drugs show promise, most do not offer a cure and some, like imatinib, have undesirable side effects.
An overview of conventional and investigational phosphodiesterase 5 inhibitors for treating erectile dysfunction and other conditions.
Expert Opin Investig Drugs
September 2024
Department of Urology, Suez Canal University, Ismailia, Egypt.
Introduction: There is a rising concern about developing innovative, efficacious PDE5I molecules that provide better safety, efficacy, and tolerability with less adverse effects. Innovative PDE5I with dual targets have also been defined in the literature. Additionally, some of PDE5I are able to selectively inhibit other enzymes such as histone deacetylase, acetylcholine esterase, and cyclooxygenase or act as nitric oxide donors.
View Article and Find Full Text PDFPostmicturition dribble in men with no previous urogenital surgery: Systematic review and meta-analysis of treatment modalities.
Neurourol Urodyn
September 2024
Urology Department, Hamad Medical Corporation, Doha, Qatar.
Introduction: Postmicturition dribble (PMD) is common in males. Little is known about PMD etiology, but it is either secondary to urethral/prostatic surgery or primary (no previous surgery). Despite PMD's high prevalence, the effectiveness of its treatment modalities remains lacking.
View Article and Find Full Text PDFThe Effect of Udenafil on Heart Rate and Blood Pressure in Adolescents With the Fontan Circulation.
Am J Cardiol
January 2024
Departments of Cardiology and Pediatrics, Cedars-Sinai Guerin Children's and Smidt Heart Institute, Los Angeles, California.
The Fontan Udenafil Exercise Longitudinal (FUEL) trial showed that treatment with udenafil was associated with improved exercise performance at the ventilatory anaerobic threshold in children with Fontan physiology. However, it is not known how the initiation of phosphodiesterase 5 inhibitor therapy affects heart rate and blood pressure in this population. These data may help inform patient selection and monitoring after the initiation of udenafil therapy.
View Article and Find Full Text PDFPhosphodiesterase 5 inhibitors: preclinical and early-phase breakthroughs for impotence treatments.
Expert Opin Investig Drugs
November 2023
Department of Urology, Tulane University School of Medicine, New Orleans, LA, USA.
Introduction: Erectile dysfunction (ED) is a condition that affects millions of men worldwide and is characterized by the inability to achieve or maintain an erection for satisfactory sexual performance. There are numerous treatment options for ED, including medications, mechanical assist devices, and surgical management; however, first-line treatment is usually a phosphodiesterase 5 (PDE5) inhibitor. There is a growing interest in developing novel, efficacious PDE5 inhibitors that provide better quality, safety, and tolerability profiles with less adverse effects.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!